Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| QURE | CLUSTER | neutral | 2/10 | Three uniQure directors each sold ~$54K of stock on June 11, 2026, totaling ~$162K, a trivial 0.01% of the $1.7B market | Jun 12, 2026 |
| LGND | CLUSTER | neutral | 2/10 | Two directors at Ligand Pharmaceuticals sold a combined ~$1.31M in shares over two days, representing 0.026% of the comp | Jun 12, 2026 |
| XOMA | DEFA14A | bullish | 8/10 | XOMA Royalty Corp filed additional definitive proxy soliciting materials (DEFA14A) confirming its acquisition by Ligand | Jun 12, 2026 |
| XOMA | 8-K | neutral | 4/10 | XOMA Royalty Corp announced that the previously announced acquisition by Ligand Pharmaceuticals is expected to close on | Jun 12, 2026 |
| TVGN | S-3 | bearish | 5/10 | Tevogen Bio filed an S-3 shelf registration to register up to 375,000 shares of common stock for resale by The Patel Fam | Jun 12, 2026 |
| BIAF | S-1 | bearish | 6/10 | bioAffinity Technologies filed an S-1 registration statement for a best-efforts public offering of up to 2,631,579 share | Jun 12, 2026 |
| IPSC | CLUSTER | neutral | 2/10 | Two insiders at Century Therapeutics (IPSC) sold a combined ~$1,632 in open-market sales on June 8, 2026, while five dir | Jun 12, 2026 |
| TRIB | 6-K | bearish | 6/10 | Trinity Biotech filed a 6-K on June 12, 2026, announcing a new at-the-market (ATM) offering agreement with Lucid Capital | Jun 12, 2026 |
| XRTX | 6-K | neutral | 3/10 | XORTX Therapeutics voluntarily delists from the TSX Venture Exchange to reduce costs and regulatory complexity, while ke | Jun 12, 2026 |
| CLYM | 8-K | bearish | 5/10 | Climb Bio entered into a new at-the-market (ATM) equity distribution agreement with Jefferies LLC for up to $100 million | Jun 12, 2026 |
| ELVN | 424B5 | bearish | 6/10 | Enliven Therapeutics filed a 424B5 prospectus supplement for a follow-on public offering of 8,933,334 shares of common s | Jun 12, 2026 |
| IVA | 6-K | mixed | 6/10 | Inventiva closed a multi-step capital restructuring on June 12, 2026: repaying €62.2M in EIB loans, repurchasing ~2.97M | Jun 12, 2026 |
| CLYM | 424B5 | bearish | 6/10 | Climb Bio filed a prospectus supplement for an at-the-market (ATM) offering of up to $100 million in common stock throug | Jun 12, 2026 |
| OCUL | 8-K | neutral | 3/10 | Ocular Therapeutix filed an 8-K reporting the formal appointment of Jason Robins as CFO (previously interim) and stockho | Jun 12, 2026 |
| TRIB | 424B5 | bearish | 6/10 | Trinity Biotech filed a 424B5 prospectus supplement to establish a new at-the-market (ATM) offering facility with Lucid | Jun 12, 2026 |
| CMND | 3 | neutral | 2/10 | HRT Financial LP filed a Form 3 initial statement of beneficial ownership of securities in Clearmind Medicine Inc. (CMND | Jun 12, 2026 |
| BCRX | 8-K | neutral | 3/10 | BioCryst held its 2026 Annual Meeting on June 11, 2026, where shareholders approved an amendment to the Stock Incentive | Jun 12, 2026 |
| CAMP | 8-K | neutral | 3/10 | Camp4 Therapeutics held its 2026 Annual Meeting on June 10, 2026, where stockholders elected three Class II directors, r | Jun 12, 2026 |
| INDV | CLUSTER | neutral | 4/10 | Two senior insiders at Indivior (CFO and CSO) sold a combined $2.06M in open-market sales over a 4-day window. While the | Jun 12, 2026 |
| DARE | 8-K | neutral | 2/10 | Dare Bioscience's 2026 annual meeting results were reported via 8-K, with all 8 proposals passing, including director el | Jun 12, 2026 |
| ADTX | CLUSTER | bearish | 6/10 | Aditxt insiders, HRT Financial LP (10% owner) and 10% owner Sandie Gong, sold a combined ~2.93M shares for ~$47K in a si | Jun 12, 2026 |
| SMMT | CLUSTER | bullish | 6/10 | Both co-CEOs of Summit Therapeutics (SMMT) each purchased 3.81M shares open-market on June 12, 2026, at $13.12, aggregat | Jun 12, 2026 |
| IONS | 8-K | neutral | 3/10 | Ionis reported positive new data from the open-label extension study (CORE-OLE) of olezarsen for severe hypertriglycerid | Jun 12, 2026 |
| CRMD | INST-CLUSTER | bullish | 7/10 | A strong institutional cluster formed in CRMD during Q4 2024, with 8 buyers (net +$14.6M) overwhelming 3 sellers (net -$ | Jun 12, 2026 |
| TNYA | INST-CLUSTER | bearish | 4/10 | Tenaya Therapeutics (TNYA) institutional cluster for Q3 2024 shows net distributing activity, with Adage Capital Partner | Jun 12, 2026 |
| LYEL | PRESS-RELEASE | neutral | 4/10 | Lyell Immunopharma presented updated Phase 1/2 safety and translational data for its CAR T-cell therapy ronde-cel at EHA | Jun 12, 2026 |
| GELS | PRESS-RELEASE | neutral | 4/10 | Gelteq announced successful veterinary palatability trials with Kemin Industries, validating its gel-based drug delivery | Jun 12, 2026 |
| TVTX | 144 | neutral | 2/10 | Director Timothy Coughlin filed a Form 144 to sell 10,000 common shares of Travere Therapeutics (TVTX), valued at approx | Jun 12, 2026 |
| RLAY | INST-CLUSTER | bullish | 6/10 | Relay Therapeutics saw a strong net buying cluster in Q3 2024, with 12 institutional buyers adding $71.5M versus 7 selle | Jun 12, 2026 |
| HUMA | INST-CLUSTER | bullish | 5/10 | A strong institutional cluster formed in HUMA during 2024-Q3, with 15 buyers accumulating $10.9M in holdings (net +$6.4M | Jun 12, 2026 |